Is OPCH a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Option Care Health (OPCH) rests on Acute infusion demand and hospital partnerships: Acute revenue, covering therapies like anti-infectives and nutrition support delivered after hospital discharge, has been growing at high single digits. Revenue (TTM) is ~$5.7B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. Whether OPCH is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Option Care Health (Nasdaq: OPCH) delivers medications through intravenous and other infusion therapies in patients' homes and at alternate-site suites, covering both acute needs (like post-hospital antibiotics and nutrition) and chronic conditions (such as immune, neurologic, and inflammatory diseases). It runs a nationwide network of pharmacies and nursing infrastructure, partners with drug manufacturers for distribution, and contracts with payers and health systems, making it the largest standalone player in a fragmented home-infusion market where the top few providers hold roughly a third of share. The investment picture in 2026 is one of a defensive, cash-generative business working through a soft patch. Revenue is running around $5.7 billion but growing only about 1 percent as acute chronic-inflammatory-drug (CID) portfolio headwinds, including Stelara and biosimilar census resets, drag on the top line. Management has kept its adjusted EBITDA and adjusted EPS guidance intact, and the stock trades at a below-market earnings multiple, so the debate centers on whether the current drug-mix pressure is transitory or a sign of structural reimbursement and competitive risk in a business with thin margins on high drug pass-through revenue.
What's the case for buying OPCH?
1. Acute infusion demand and hospital partnerships
Acute revenue, covering therapies like anti-infectives and nutrition support delivered after hospital discharge, has been growing at high single digits. As health systems push to move care out of expensive hospital settings, Option Care's national footprint positions it to capture referral volume and consolidate patients, including some exiting CVS Coram's acute business.
2. Margin and cost discipline holding profit targets
Despite a low-single-digit revenue backdrop, management maintained full-year adjusted EBITDA guidance of roughly $480 to $505 million and adjusted EPS of about $1.82 to $1.92, implying mid-single-digit EBITDA and high-single-digit EPS growth at the midpoint. The mix shift toward higher-margin acute work and operating leverage support this even as chronic revenue softens.
3. Cash generation and capital allocation
The company converts earnings into meaningful free cash flow, with trailing levered free cash flow near $170 million and analyst estimates in the $300 million range looking forward. That cash has funded buybacks and tuck-in acquisitions like Intramed Plus, giving management levers to compound per-share value while the top line is muted.
4. Structural tailwind from site-of-care migration
The broader home-infusion market is estimated to grow at a mid-single-digit to low-double-digit rate as payers and patients favor lower-cost home settings over hospitals and clinics. As the scaled independent leader, Option Care is a natural consolidator in a fragmented field of regional and hospital-affiliated providers.
What are the risks to OPCH?
The most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. Because infusion revenue carries large drug pass-through costs, gross margins are thin and sensitive to reimbursement changes, payer contract terms, and manufacturer distribution economics. Competition from CVS Coram, Optum-affiliated Naven Health, and hospital-owned programs pressures pricing and referral flow. Broader policy risk around drug pricing, Medicare and Medicaid rates, and specialty-pharmacy reimbursement could compress economics. Management framed the census reset as a one-time 2026 event with no 2027 carryover, but if chronic declines persist, growth and the profit guidance could come under renewed pressure.
How is OPCH valued? (as of JULY 2026)
Snapshot for OPCH as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$5.7B
- FY2026 revenue guidance: ~$5.68B to $5.78B
- Adjusted EBITDA (FY2026 guide): ~$480M to $505M
- Adjusted EPS (FY2026 guide): ~$1.82 to $1.92
- Market cap: ~$3.4B
- P/E (trailing / forward): ~17x / ~12x
OPCH trades around the low $20s with a market cap near $3.4 billion, a forward P/E in the low teens that sits well below the broader market and many healthcare-services peers. The discount reflects the flat 2026 revenue outlook and drug-mix headwinds rather than a distressed balance sheet, and trailing free cash flow near $170 million underpins the profile.
How do you decide if OPCH is a buy?
Rather than asking whether OPCH is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold OPCH indirectly through an index or sector ETF before adding more.
For the full picture, see the OPCH stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about OPCH against your real portfolio and see your actual exposure before deciding.
The bottom line on OPCH
The bottom line: Option Care Health's story right now is Acute infusion demand and hospital partnerships, with revenue (ttm) at ~$5.7B. If you believe that narrative continues, the call is about sizing OPCH sensibly and checking overlap with what you own; if you doubt it (the risk: the most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around OPCH with Walnut
Use Option Care Health as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is OPCH a good stock to buy right now?
+
The case for Option Care Health right now is Acute infusion demand and hospital partnerships, with revenue (ttm) at ~$5.7B. If you believe that thesis holds, OPCH is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Option Care Health do?
+
Option Care Health (Nasdaq: OPCH) delivers medications through intravenous and other infusion therapies in patients' homes and at alternate-site suites, covering both acute needs (
What are the main risks of OPCH?
+
The most immediate risk is the drug-portfolio (CID) headwind, an estimated 600 basis point revenue drag and roughly $55 million gross-profit hit in 2026 tied to Stelara and biosimilar transitions and heavier patient benefit reverification workloads. Because infusion revenue carries large drug pass-through costs, gross margins are thin and sensitive to reimbursement changes, payer contract terms, and manufacturer distribution economics. Competition from CVS Coram, Optum-affiliated Naven Health, and hospital-owned programs pressures pricing and referral flow. Broader policy risk around drug pricing, Medicare and Medicaid rates, and specialty-pharmacy reimbursement could compress economics. Management framed the census reset as a one-time 2026 event with no 2027 carryover, but if chronic declines persist, growth and the profit guidance could come under renewed pressure.
What does Option Care Health do?
+
It provides infusion therapy, delivering medications intravenously or by other infusion routes in patients' homes and at alternate-site suites. Its therapies span acute needs like post-hospital antibiotics and nutrition and chronic conditions such as immune, neurologic, and inflammatory diseases.
Is Option Care Health profitable?
+
Yes. It generates positive net income (roughly $200 million on a trailing basis) and meaningful free cash flow, with FY2026 adjusted EBITDA guidance of about $480 to $505 million. Margins are thin because much of its revenue is drug pass-through cost.
Why is OPCH revenue barely growing in 2026?
+
Management cited a roughly 600 basis point headwind from its acute chronic-inflammatory-drug (CID) portfolio, including Stelara and biosimilar census resets and heavier benefit reverification work. Acute therapy is growing high single digits while chronic revenue has declined slightly.
How big is the home infusion market?
+
Industry estimates put the US and global home-infusion market in the tens of billions of dollars, growing at a mid-single-digit to low-double-digit annual rate as care shifts from hospitals to lower-cost home and alternate-site settings.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell OPCH; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.